Quarterly ResultMay 14, 2026, 05:07 PM
Nuo Therapeutics Q1 Revenue +169% to $1.3M; Going Concern Doubt
AI Summary
Nuo Therapeutics reported a significant increase in total revenue for Q1 2026, rising 169% to $1.30 million, and a 17% improvement in net loss to $(0.62) million. The company also secured $1.0 million in new notes payable in January 2026. However, cash balances decreased, total liabilities increased, and management expressed substantial doubt about its ability to continue as a going concern due to insufficient resources for the next 12 months.
Key Highlights
- Q1 2026 total revenue increased 169% to $1.30 million from $0.48 million in Q1 2025.
- Net loss improved by 17% to $(0.62) million in Q1 2026 from $(0.75) million in Q1 2025.
- Loss per common share was $(0.01) in Q1 2026, an improvement from $(0.02) in Q1 2025.
- Cash decreased to $0.26 million as of March 31, 2026, from $0.55 million at December 31, 2025.
- Total liabilities increased to $3.33 million from $2.80 million at December 31, 2025.
- Secured $1.0 million in new notes payable in January 2026, with an additional $0.6 million possible.
- Company expressed substantial doubt about its ability to continue as a going concern.
- Recognized $77,941 in distribution fee revenue from the Smith+Nephew agreement.